Dublin, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The immune checkpoint inhibitors market will register a CAGR of almost 3% by 2023.

The growing number of cancer cases being diagnosed across the globe. Various international and national level campaigns are conducted to increase the awareness about cancer and to help early detection of the disease.

High target affinity and specificity of immune checkpoint inhibitors drugs

Most of the approved therapies for cancer treatment have severe side effects, which lowers the patient compliance towards the treatment. Thus, these drawbacks help the immune checkpoint inhibitors market grow.

High costs associated with the treatment

Treatment cost is one of the major challenges for cancer patients. The high cost is mainly due to hospitalization, laboratory costs, and novel immunotherapies.

Competitive Landscape

With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Pfizer

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

PART 06: MARKET SEGMENTATION BY TYPE

• Market segmentation by type
• Comparison by type
• PD-1 inhibitors - Market size and forecast 2018-2023
• CTLA-4 inhibitors - Market size and forecast 2018-2023
• Others - Market size and forecast 2018-2023
• Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic segmentation
• Geographic comparison
• Americas - Market size and forecast 2018-2023
• EMEA - Market size and forecast 2018-2023
• APAC - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

• Market drivers
• Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Pfizer

For more information about this report visit https://www.researchandmarkets.com/research/4j6td3/global_immune?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs